Limbrel

flavocoxid

(fla-vo-cox-id) ,

Limbrel

(trade name)

Classification

Therapeutic: nonopioid analgesics
Pharmacologic: flavanoids
Pregnancy Category: UK

Indications

Dietary management of osteoarthritis; considered to be a medical food product.

Action

Anti-inflammatory and analgesic properties related to inhibition of prostaglandin synthesis by inhibiting cyclo-oxygenase (not COX-2 selective) and other mediators of inflammation.

Therapeutic effects

Decreased pain/inflammation associated with osteoarthritis, with improved mobility.

Pharmacokinetics

Absorption: Some intestinal conversion prior to absorption, remainder unknown.
Distribution: Unknown.
Metabolism and Excretion: Mostly metabolized by the liver.
Half-life: Unknown.

Time/action profile (analgesic effect)

ROUTEONSETPEAKDURATION
POwithin 1–2 hrunknown12 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Obstetric / Lactation / Pediatric: Not recommended.
Use Cautiously in: History of GI bleeding.

Adverse Reactions/Side Effects

Cardiovascular

  • ↑ BP
  • ↑ in varicose veins

Gastrointestinal

  • GI upset

Dermatologic

  • psoriasis

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Oral (Adults) 250 mg every 12 hr (up to 250 mg three times daily has been used).

Availability

Capsules: 250 mg

Nursing implications

Nursing assessment

  • Assess pain (note type, location, and intensity), range of motion, degree of swelling, and stiffness in affected joints before and periodically during therapy.

Potential Nursing Diagnoses

Chronic pain (Indications)

Implementation

  • Oral: Administer flavocoxid twice daily.

Patient/Family Teaching

  • Instruct patient to take flavocoxid as directed. Do not increase does without consulting health care professional.

Evaluation/Desired Outcomes

  • Decrease in pain and stiffness, and improved mobility in patients with osteoarthritis.

Limbrel

a trademark for flavocoxid.
Mentioned in ?
References in periodicals archive ?
M2 PHARMA-November 22, 2017-FDA Warns Consumers about Potentially Life-Threatening Health Problems Linked to Limbrel
The US Food and Drug Administration is advising consumers not to use Limbrel, a product in capsule form currently being manufactured as a medical food to manage the metabolic processes associated with osteoarthritis, the agency said.
FDA Warns Consumers about Potentially Life-Threatening Health Problems Linked to Limbrel
In 2006, Limbrel (flavocoxid), the first medical food for the management of osteoarthritis launched.
Medical foods: opportunities in an emerging market: a unique space between dietary supplements and pharmaceuticals, the medical foods category may offer novel growth for research-focused companies
For example, Limbrel, a medical food from Primus Pharmaceuticals of Scottsdale, Ariz.
Now along comes Limbrel, each capsule containing 250 mg of flavocoxid.
Medical food category gains traction
announces the issuance of a new composition of matter patent for Limbrel, the first prescription medical food product to safely meet the distinctive nutritional requirements of patients with osteoarthritis (OA).
Limbrel contains flavocoxid, a proprietary composition of natural flavonoid ingredients from the plant sources of Scutellaria baicalensis and Acacia catechu that meet the FDA strict safety standard of Generally Recognized As Safe (GRAS).
New Patent Issued for Limbrel[R]
Flavocoxid is currently available in two commercially marketed medical food products under the supervision of a qualified licensed health-care provider: Limbrel, a medical food available in 250 mg and 500 mg versions through conventional prescription pharmacy fulfillment (Primus Pharmaceuticals Inc.
Flavocoxid: a medicinal extract of Scutellaria bicalensis and Acacia catechu acts as a dual inhibitor of cyclooxegenase and 5-lipoxegenase to reduce inflammation
In this study, the Limbrel and naproxen groups performed nearly identically, showing significant overall improvements in conventional osteoarthritis efficacy measures, including physician and subject global assessments, and WOMAC, a key measure of mobility, stiffness and joint discomfort," said the lead author Robert Levy, M.
New Clinical Study Shows Limbrel(TM) as Effective as Naproxen for Knee Osteoarthritis
First, in the medical food category, Limbrel (made and patented by Primus Pharmaceuticals, Scottsdale, AZ) is the first prescription product developed to meet the nutritional requirements of patients with osteoarthritis through dual inhibition of arachidonic acid metabolism.
A scientific & organizational quality system: a practical guide for botanical and dietary supplement companies; Designing and implementing a scientific and organizational quality system for the botanical and dietary supplement industry will be a necessary requirement for those companies that want to be successful in the future
Limbrel contains flavocoxid, a proprietary blend of natural ingredients from phytochemical food source materials.
Prescription osteoarthritis product
The company claims that Limbrel delivers antioxidant benefit in a highly concentrated form that cannot be obtained simply by changing one's normal diet.
Antioxidants: finding the right balance; An overview of the issues and new developments in a crowded antioxidant market

Medical browser ?
Full browser ?